ProCE Banner Activity

Cardiology Call to Action: Embracing Glucose-Lowering Treatment to Lower CV Risk in Patients With T2D

Clinical Thought

Here's my take on why it is important for cardiologists to embrace glucose-lowering and CV risk–reducing therapies such as GLP-1 RAs and SGLT2 inhibitors in their patients with T2D.

Released: October 17, 2023

Expiration: October 17, 2024

Share

Faculty

Anne Peters

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk

Faculty Disclosure

Primary Author

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Anne Peters, MD: consultant/advisor/speaker: Abbott Diabetes Care, Lilly, Vertex, Zealand; researcher: Abbott Diabetes Care, Insulet; stock/stock options: Omada Health, Teladoc.